The Government has published the level of payment due from members of the Pharmaceutical Price Regulation Scheme (PPRS) in 2017 to keep health service spend on branded medicines within the levels agreed under the Scheme.
The UK pharmaceutical industry trade body, the Association of the British Pharmaceutical Industry (ABPI), have responded to the Prime Minister's speech on the Government's negotiating objectives for exiting the EU.
Read ABPI Chief Executive Stephen Whitehead's speech at the PharmaTimes debate with Ben Goldacre where the final vote on the motion 'Pharma is not getting its act together' swung in favour of industry.
Thank you, Stephen and Simon, for those very kind words. Ladies and gentlemen, it's unusual for a new President to say a lot at their first dinner. Traditionally we accept the chain and allow the outgoing President their last farewell speech.
Ladies and gentlemen ... It falls to me to thank you all for coming to our event today.
Stephen Whitehead, Chief Executive of the ABPI, took part in an interview on BBC Radio 4’s Today programme on the subject of clinical trial data.
The creation of the NICE Implementation Collaborative (NIC) harnesses the skills, experience and dedication of organisations and individuals from across the healthcare system to improve patient outcomes for all.
The ABPI is hosting a workshop to facilitate discussions on how best to address the issue of historical data and disclosure requirements on Thursday 21 March.
The Department of Health has today [27 October] published the Q2 2017 PPRS data showing that the pharmaceutical industry has paid a total of £190 million during the first two quarters of 2017 under the 2014 Pharmaceutical Price Regulation Scheme (PPRS).
Roche Products Limited has been reinstated to membership of the Association of the British Pharmaceutical Industry (ABPI) following the company’s suspension from 14 July 2008.
The UK’s life sciences trade associations believe the package of measures announced today by the Office for Life Sciences provide an excellent basis for firmly securing the future of the life sciences sector.